{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-004490","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.323667+00:00","generated_at":"2026-06-27T02:54:01.860182+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neoleukin reports 2021 net loss of $60.7M, cash $142.5M; NL-201 interim data expected H2 2022","bullets":["Net loss $60.7M in 2021 vs $33.3M in 2020; cash & equivalents $142.5M down from $192.6M; runway into H2 2023.","Phase 1 interim data for NL-201 in solid tumors expected H2 2022; combination trial with pembrolizumab planned.","R&D expenses $39.2M (up 61%), G&A $21.5M (up 25%) driven by clinical activities and personnel costs.","Rohan Palekar (CEO of 89bio) appointed to board; Lewis Williams resigns; Drachman named PFO, Smith named PAO."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-004490","json":"https://secwatch.observer/filing/0001628280-22-004490.json","markdown":"https://secwatch.observer/filing/0001628280-22-004490.md","text":"https://secwatch.observer/filing/0001628280-22-004490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/nltx-20220225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:54:01.860182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44fce742ac","claim":"Lewis T. Williams resigned as Director at Neurogene Inc..","evidence_excerpt":"the Board accepted the resignation of Lewis T. “Rusty” Williams as a member of the Board and its committees, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5b88658a31","claim":"Rohan Palekar was appointed as Director at Neurogene Inc..","evidence_excerpt":"the Board appointed Rohan Palekar as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6d6a00caa6","claim":"Sean Smith was appointed as Principal Accounting Officer at Neurogene Inc..","evidence_excerpt":"the Board appointed Sean Smith, the Company’s VP, Finance and Controller, as the Company’s Principal Accounting Officer, effective on the Appointment Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"ca892f3500","claim":"Jonathan Drachman was appointed as Principal Financial Officer at Neurogene Inc..","evidence_excerpt":"the Board appointed Jonathan Drachman, the Company’s Chief Executive Officer, as the Company’s Principal Financial Officer, effective on March 2, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1404644/000162828022004490/0001628280-22-004490-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}